Bicyclic aminoimidazolone BACE1 inhibitors

Abstract

This application describes the further evolution of non-peptidic inhibitors of β-amyloid cleaving enzyme (BACE1) for the treatment of Alzheimer's disease. While this is part of a significant effort at Wyeth, these compounds are only moderately potent. Thus, this patent does not appear to contain any development candidates with the claimed mechanism of action.

Keywords::

• Alzheimer's disease
• aspartyl protease inhibitors
• β-amyloid cleaving enzyme (BACE1)
• β-secretase